Centogene N.V.

About Centogene N.V.

CENTOGENE is dedicated to guiding precision medicine through advanced diagnostics. Their mission is to empower precision medicine by providing solutions for better prevention, diagnosis, and treatment for patients, working closely with physicians and pharma partners to deliver personalized therapies and accelerate drug discovery.

Products & Services

CentoCustom Panel:A customizable testing solution that allows physicians to create tailored gene panels for each patient's clinical needs.

CentoGenome:Whole Genome Sequencing (WGS) offering a comprehensive one-step solution with high diagnostic yield, including ultra-fast results in 5 business days.

CentoXome:Whole Exome Sequencing (WES) for quicker and cost-effective diagnosis of patients with complex and unclear symptoms.

MOx - Multiomic Solutions:Provides a deeper understanding of biological processes for early diagnosis through multiomics.

NGS Panels:Tests for a wide selection of hereditary genetic conditions, offering a fast and cost-effective diagnostic tool.

CentoNIPT:Non-invasive prenatal test (NIPT) screening for common fetal chromosomal abnormalities with expert medical reporting.

Pharma Solutions:Services for pharma partners including clinical trial support, patient identification, drug discovery, and development using multiomic insights.

CentoDx:An end-to-end genomic knowledge management platform for streamlined variant interpretation and state-of-the-art genetic diagnosis.

CENTOGENE Biodatabank:A biodatabank with data from over 1 million individuals, supporting research and diagnostics.

Specialties

Precision Medicine Genetic Diagnostics Whole Genome Sequencing Whole Exome Sequencing Multiomic Solutions Non-Invasive Prenatal Testing (NIPT) Bioinformatics Rare Disease Diagnostics Pharma Clinical Trial Support

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Strategic Transaction T: - FT: Strategic Transaction	A: 8717906 MR: - FA: EUR 8,717,906.80 FAN: 8717906	D: 2024-11-13 FD: 2024-11-13	1 investors
2	RT: Debt T: - FT: Debt	A: 20000000 MR: - FA: approximately $20 million FAN: 20000000	D: 2024-05-15 FD: 2024-05-15	1 investors

Strategic Transaction Latest

2024-11-13

$8.7M

1 investor (Pro only)

Debt 2024-05-15

$20.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David Jiménez

Chief Executive Officer

P

Prof. Peter Bauer, M.D.

Chief Medical and Genomic Officer

F

Francisco Valor Martínez

Chief Financial Officer

V

Víctor Llinares

Chief Commercial Officer

M

Marcia Riboldi

CEO CENTOGENE Brazil and Latin America

A

Andy Chang

Chief Executive Officer, Asia Pacific

View 6 more team members with Pro

Unlock Full Team Directory

Recent News

Centogene N.V. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised